Stephen L. Eck - Feb 15, 2025 Form 4 Insider Report for MACROGENICS INC (MGNX)

Role
Chief Medical Officer
Signature
Beth A. Smith, Attorney-in-fact
Stock symbol
MGNX
Transactions as of
Feb 15, 2025
Transactions value $
-$12,652
Form type
4
Date filed
2/19/2025, 04:20 PM
Previous filing
Feb 11, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MGNX Common Stock Options Exercise $0 +16.7K +94.4% $0.00 34.3K Feb 15, 2025 Direct F1
transaction MGNX Common Stock Tax liability -$12.7K -4.94K -14.4% $2.56 29.4K Feb 15, 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MGNX Restricted Stock Unit Options Exercise $0 -16.7K -50% $0.00 16.7K Feb 15, 2025 Common Stock 16.7K $0.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 15, 2023, the reporting person was granted 50,000 restricted stock units, 33% of which vested on February 15, 2024 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis.